102 related articles for article (PubMed ID: 2908853)
1. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes.
Relling MV; Evans WE; Fonné-Pfister R; Meyer UA
Cancer Res; 1989 Jan; 49(1):68-71. PubMed ID: 2908853
[TBL] [Abstract][Full Text] [Related]
2. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
3. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.
Wienkers LC; Wurden CJ; Storch E; Kunze KL; Rettie AE; Trager WF
Drug Metab Dispos; 1996 May; 24(5):610-4. PubMed ID: 8723744
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
Draper AJ; Madan A; Parkinson A
Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
[TBL] [Abstract][Full Text] [Related]
5. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.
Chiba K; Kobayashi K; Manabe K; Tani M; Kamataki T; Ishizaki T
J Pharmacol Exp Ther; 1993 Jul; 266(1):52-9. PubMed ID: 8331574
[TBL] [Abstract][Full Text] [Related]
6. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
[TBL] [Abstract][Full Text] [Related]
7. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.
Chiba K; Saitoh A; Koyama E; Tani M; Hayashi M; Ishizaki T
Br J Clin Pharmacol; 1994 Mar; 37(3):237-42. PubMed ID: 8198931
[TBL] [Abstract][Full Text] [Related]
8. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes.
Kobayashi K; Yamamoto T; Chiba K; Tani M; Ishizaki T; Kuroiwa Y
Br J Clin Pharmacol; 1995 Nov; 40(5):481-5. PubMed ID: 8703653
[TBL] [Abstract][Full Text] [Related]
9. Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes.
Horsmans Y; Lannes D; Larrey D; Tinel M; Letteron P; Loeper J; Pessayre D
Xenobiotica; 1991 Dec; 21(12):1559-70. PubMed ID: 1785203
[TBL] [Abstract][Full Text] [Related]
10. Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes.
Hall SD; Guengerich FP; Branch RA; Wilkinson GR
J Pharmacol Exp Ther; 1987 Jan; 240(1):216-22. PubMed ID: 2879902
[TBL] [Abstract][Full Text] [Related]
11. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction.
Shimada T; Misono KS; Guengerich FP
J Biol Chem; 1986 Jan; 261(2):909-21. PubMed ID: 3079764
[TBL] [Abstract][Full Text] [Related]
12. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.
Inaba T; Jurima M; Mahon WA; Kalow W
Drug Metab Dispos; 1985; 13(4):443-8. PubMed ID: 2863108
[TBL] [Abstract][Full Text] [Related]
13. Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6.
Xu BQ; Ishii M; Ding LR; Fischer NE; Inaba T
Life Sci; 2003 Mar; 72(17):1953-62. PubMed ID: 12597994
[TBL] [Abstract][Full Text] [Related]
14. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A.
Ring BJ; Binkley SN; Vandenbranden M; Wrighton SA
Br J Clin Pharmacol; 1996 Mar; 41(3):181-6. PubMed ID: 8866916
[TBL] [Abstract][Full Text] [Related]
15. Characterization of monkey cytochrome P450, P450 CMLd, responsible for S-mephenytoin 4-hydroxylation in hepatic microsomes of cynomolgus monkeys.
Ohmori S; Chiba K; Nakasa H; Horie T; Kitada M
Arch Biochem Biophys; 1994 Jun; 311(2):395-401. PubMed ID: 8203903
[TBL] [Abstract][Full Text] [Related]
16. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
17. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.
Ko JW; Desta Z; Soukhova NV; Tracy T; Flockhart DA
Br J Clin Pharmacol; 2000 Apr; 49(4):343-51. PubMed ID: 10759690
[TBL] [Abstract][Full Text] [Related]
18. Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes.
He N; Xie HG; Collins X; Edeki T; Yan Z
Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):813-5. PubMed ID: 16922812
[TBL] [Abstract][Full Text] [Related]
19. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes.
Srivastava PK; Yun CH; Beaune PH; Ged C; Guengerich FP
Mol Pharmacol; 1991 Jul; 40(1):69-79. PubMed ID: 1857342
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6.
Masimirembwa CM; Hasler JA; Johansson I
Eur J Clin Pharmacol; 1995; 48(1):35-8. PubMed ID: 7621845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]